MCID: BLD048
MIFTS: 53

Bladder Transitional Cell Carcinoma malady

Nephrological diseases, Cancer diseases categories

Summaries for Bladder Transitional Cell Carcinoma

About this section
Sources:
32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Bladder Transitional Cell Carcinoma, also known as transitional cell carcinoma of bladder, is related to transitional cell carcinoma and bladder carcinoma. An important gene associated with Bladder Transitional Cell Carcinoma is CDKN1A (cyclin-dependent kinase inhibitor 1A (p21, Cip1)), and among its related pathways are Toll-like Receptor Pathway and HIF-1 signaling pathway. The compounds estrogen and hrgbeta1 have been mentioned in the context of this disorder. Affiliated tissues include endothelial, prostate and lymph node, and related mouse phenotypes are no phenotypic analysis and cardiovascular system.

Aliases & Classifications for Bladder Transitional Cell Carcinoma

About this section
Sources:
8Disease Ontology, 10DISEASES, 60UMLS, 44Novoseek, 39NCIt, 56SNOMED-CT
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases
Anatomical: Nephrological diseases


Aliases & Descriptions:

bladder transitional cell carcinoma 8 10
transitional cell carcinoma of bladder 8 60
urinary bladder urothelial carcinoma 8
carcinoma transitional cell bladder 44


External Ids:

Disease Ontology8 DOID:4006
NCIt39 C39851

Related Diseases for Bladder Transitional Cell Carcinoma

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Bladder Transitional Cell Carcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 95)
idRelated DiseaseScoreTop Affiliating Genes
1transitional cell carcinoma31.9IFI27, FABP4, UPK1A, EGFR, CDKN1A, ERBB2
2bladder carcinoma31.9TP53, ERBB2, CDKN1A
3bladder carcinoma in situ30.6TP53, ERBB2, BLCAP, EGFR
4inverted papilloma30.3IFI27, KRT13
5papilloma30.3IFI27, CDKN1A, KRT13, TP53
6lung adenocarcinoma30.3EGFR, CDKN1A, HPGD, ERBB2, TP53
7adenocarcinoma30.3IFI27, EGFR, CDKN1A, MMP10, KRT13, ERBB2
8invasive bladder transitional cell carcinoma10.7
9in situ carcinoma10.4
10prostate transitional cell carcinoma10.3
11prostatitis10.3
12clear cell adenocarcinoma10.3
13signet ring cell adenocarcinoma10.3
14pleomorphic carcinoma10.3
15spindle cell carcinoma10.3
16bladder signet ring cell adenocarcinoma10.3
17large cell carcinoma10.3
18bladder clear cell adenocarcinoma10.3
19inverted transitional papilloma10.2
20papillary carcinoma10.2
21papillary transitional carcinoma10.2
22sarcomatoid transitional cell carcinoma10.2
23bladder urothelial papillary carcinoma10.2
24amyloidosis10.2
25bone carcinoma10.2
26prostate small cell carcinoma10.2
27small cell carcinoma10.2
28ovary transitional cell carcinoma10.2
29bladder adenocarcinoma10.2
30bladder disease10.2
31bladder diverticulum10.2
32bladder transitional cell papilloma10.2
33cervicitis10.2
34herpes simplex10.2
35lung small cell carcinoma10.2
36prostate adenocarcinoma10.2
37renal pelvis carcinoma10.2
38renal pelvis transitional cell carcinoma10.2
39transitional papilloma10.2
40gastrointestinal stromal tumor10.0IFI27
41cervical adenocarcinoma10.0CDKN1A, IFI27
42osteosarcoma10.0TP53, CDKN1A
43tongue cancer10.0CDKN1A
44leukoplakia10.0IFI27, KRT13
45esophageal cancer10.0TP53, EGFR
46laryngeal squamous cell carcinoma10.0IFI27, EGFR, CDKN1A, TP53
47uterine carcinosarcoma10.0ERBB2
48ductal carcinoma in situ10.0EGFR, ERBB2, TP53
49oral cavity cancer10.0TP53
50cervical intraepithelial neoplasia10.0IFI27

Graphical network of the top 20 diseases related to Bladder Transitional Cell Carcinoma:



Diseases related to bladder transitional cell carcinoma

Clinical Features for Bladder Transitional Cell Carcinoma

About this section

Drugs & Therapeutics for Bladder Transitional Cell Carcinoma

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials, 60UMLS, 40NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Bladder Transitional Cell Carcinoma

Drug clinical trials:

Search ClinicalTrials for Bladder Transitional Cell Carcinoma

Search NIH Clinical Center for Bladder Transitional Cell Carcinoma

Search CenterWatch for Bladder Transitional Cell Carcinoma

Genetic Tests for Bladder Transitional Cell Carcinoma

About this section

Anatomical Context for Bladder Transitional Cell Carcinoma

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Bladder Transitional Cell Carcinoma:

32
Endothelial, Prostate, Lymph node, Lung, Testes, Ovary, Kidney, Brain, Testis, Adipocyte, Heart, Cervix, Monocytes, Dentritic cells, Bone

Animal Models for Bladder Transitional Cell Carcinoma or affiliated genes

About this section
Sources:
36MGI
See all sources

MGI Mouse Phenotypes related to Bladder Transitional Cell Carcinoma:

36
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000301210.3TP53, FGF3, CDKN1A, NR2F1, EGFR, HEPACAM
2MP:000538510.1TP53, FABP5, FABP4, EGFR, CDKN1A, HPGD
3MP:000537510.0FABP5, FABP4, EGFR, CDKN1A, TP53

Publications for Bladder Transitional Cell Carcinoma

About this section
Sources:
50PubMed
See all sources

Articles related to Bladder Transitional Cell Carcinoma:

(show top 50)    (show all 629)
idTitleAuthorsYear
1
Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. (23609182)
2013
2
A case of unusual mast cell response with interstitial cystitis-like symptoms to neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder. (24335680)
2013
3
High-grade Transitional Cell Carcinoma of the Bladder in a 5-Year-Old Boy Successfully Treated With Partial Cystectomy and Intravesical Bacillus Calmette-Guerin. (23619109)
2013
4
Recurrent transitional cell carcinoma of the bladder: A mixed nested variant case report and literature review. (22511434)
2012
5
Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review. (22937482)
2012
6
Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. (21756352)
2011
7
Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. (21976924)
2011
8
Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray. (21251473)
2011
9
Transitional cell carcinoma of the urinary bladder in a 14-year-old dog. (22131588)
2011
10
A one-port pneumovesicum method in en bloc laparoscopic nephroureterectomy with bladder cuff resection is feasible and safe for upper tract transitional cell carcinoma. (21481129)
2011
11
Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder. (21814319)
2011
12
Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. (19404918)
2009
13
Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma. (19332900)
2009
14
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. (18538698)
2008
15
The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy. (19077398)
2008
16
Comparison of distributions of survivin among tissues from urinary bladders of dogs with cystitis, transitional cell carcinoma, or histologically normal urinary bladders. (18672973)
2008
17
Impaired delta NP63 expression is associated with poor tumor development in transitional cell carcinoma of the bladder. (18955789)
2008
18
Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. (19101898)
2008
19
The clinico-pathological significance of protein expression of PAK1 in bladder transitional cell carcinoma]. (18167251)
2007
20
EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. (17541304)
2007
21
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. (17011058)
2006
22
Survival and progression in high grade tumour subset of G2 and G3 pT1 bladder transitional cell carcinoma. (16784833)
2006
23
The detection of protein expression of clusterin and Ki-67 and the status of cell apoptosis in bladder transitional cell carcinoma]. (16620672)
2006
24
Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. (16642478)
2006
25
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. (17024120)
2006
26
Heat shock protein 70 expression in relation to apoptosis in primary bladder transitional cell carcinoma. (16438908)
2005
27
Effect of retinoic acid and interferon alpha-2a on transitional cell carcinoma of bladder. (15592090)
2005
28
Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. (15833553)
2005
29
HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. (15072912)
2004
30
Significance of activated matrix metalloproteinase 2 (MMP2) in progression of bladder transitional cell carcinoma]. (12948424)
2003
31
Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. (12651606)
2003
32
Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. (11115562)
2001
33
Risk factors for the development of bladder transitional cell carcinoma following surgery for transitional cell carcinoma of the upper urinary tract. (11490207)
2001
34
Isolation and characterization of the TERE1 gene, a gene down- regulated in transitional cell carcinoma of the bladder. (11314041)
2001
35
Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. (11712804)
2001
36
Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma. (12840920)
2000
37
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? (11051255)
2000
38
Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. (10940702)
2000
39
Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. (11108659)
2000
40
G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. (10376969)
1999
41
Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. (10197443)
1999
42
Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. (9477105)
1998
43
Re: Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. (9720567)
1998
44
Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. (9192993)
1997
45
p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. (9286659)
1997
46
TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. (8638540)
1996
47
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. (7677935)
1993
48
Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters. (1361436)
1992
49
Miliary tuberculosis secondary to transurethral bacillus Calmette-GuAcrin administration for superficial transitional cell carcinoma of the bladder. (2362292)
1990
50
Inverted papilloma of the bladder with focal transitional cell carcinoma: a case report. (3934592)
1985

Genetic Variations for Bladder Transitional Cell Carcinoma

About this section

Expression for genes affiliated with Bladder Transitional Cell Carcinoma

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Bladder Transitional Cell Carcinoma.

Pathways for genes affiliated with Bladder Transitional Cell Carcinoma

About this section
Sources:
59Tocris Bioscience, 29KEGG, 51QIAGEN, 37NCBI BioSystems Database, 12EMD Millipore, 52R&D Systems, 53Reactome, 55SinoBiological, 49PharmGKB
See all sources

Pathways related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 27)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.4TP53, ERBB2
210.4ERBB2, EGFR
3
Hide members
10.4ELK1, TP53
4
Hide members
10.4ELK1, EGFR
510.4TP53, CDKN1A, EGFR
6
Transcription Androgen Receptor nuclear signaling
Hide members
10.4EGFR, CDKN1A, ERBB2
710.4EGFR, CDKN1A, ERBB2
8
Hide members
10.4CDKN1A, TP53, ELK1
9
Development TGF-beta receptor signaling
Hide members
10.4ELK1, ERBB2, CDKN1A
10
Apoptosis and survival Apoptotic TNF-family pathways
Hide members
10.4CDKN1A, BIRC7, TP53
11
Hide members
10.4TP53, ERBB2, CDKN1A, EGFR
1210.4TP53, ERBB2, CDKN1A, EGFR
1310.4TP53, ERBB2, CDKN1A, EGFR
14
Hide members
10.4EGFR, CDKN1A, ERBB2, TP53
1510.4EGFR, CDKN1A, ERBB2, TP53
16
Hide members
10.4ERBB2, FGF3, CDKN1A, EGFR
17
Hide members
10.4EGFR, CDKN1A, FGF3, ERBB2
18
Hide members
10.4EGFR, CDKN1A, FGF3, ERBB2
19
Hide members
10.3ELK1, TP53, ERBB2, EGFR
2010.3EGFR, ERBB2, TP53, ELK1
21
Hide members
10.3EGFR, CDKN1A, FGF3, ERBB2, TP53
22
Hide members
10.3EGFR, CDKN1A, ERBB2, TP53, ELK1
23
Hide members
10.3EGFR, CDKN1A, ERBB2, TP53, ELK1
24
Hide members
10.3EGFR, FGF3, ERBB2, TP53, ELK1
2510.3ELK1, TP53, ERBB2, FGF3, CDKN1A, EGFR
2610.3EGFR, CDKN1A, FGF3, BIRC7, ERBB2, TP53
27
Hide members
10.3EGFR, CDKN1A, FGF3, MMP10, ERBB2, TP53

Compounds for genes affiliated with Bladder Transitional Cell Carcinoma

About this section
Sources:
44Novoseek, 49PharmGKB, 11DrugBank, 59Tocris Bioscience, 24HMDB, 28IUPHAR
See all sources

Compounds related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 78)
idCompoundScoreTop Affiliating Genes
1estrogen4410.9NR2F1
2hrgbeta14410.8ERBB2, CDKN1A, EGFR
3taxane4410.8CDKN1A, EGFR, TP53, ERBB2
4suberoylanilide hydroxamic acid4410.8CDKN1A, EGFR, ERBB2, TP53
5oxaliplatin44 49 1112.8EGFR, TP53, CDKN1A, ERBB2
6flavopiridol44 1111.8ERBB2, EGFR, CDKN1A, TP53
7bortezomib44 1111.8ERBB2, CDKN1A, TP53, EGFR
8irinotecan44 49 1112.8ERBB2, TP53, CDKN1A, EGFR
9temozolomide44 1111.8EGFR, CDKN1A, TP53
10thymidylate4410.8EGFR, TP53, ERBB2, CDKN1A, IFI27
11gefitinib44 49 1112.7ERBB2, CDKN1A, EGFR, IFI27
12geldanamycin44 49 59 1113.7TP53, EGFR, CDKN1A, ERBB2
13gemcitabine44 49 1112.7ERBB2, CDKN1A, TP53, EGFR
14adpribose4410.7TP53, IFI27, CDKN1A, EGFR
15optimax4410.7IFI27, CDKN1A
16p000484410.7IFI27, CDKN1A
175fluorouracil4410.7CDKN1A, BIRC7, ERBB2, TP53, EGFR
18docetaxel44 49 59 1113.7EGFR, CDKN1A, ERBB2, TP53
19doxorubicin44 49 1112.7BIRC7, CDKN1A, TP53, EGFR, IFI27, ERBB2
20retinoid4410.7EGFR, TP53, CDKN1A, FABP12, FABP4, IFI27
21resveratrol44 59 11 2413.7ERBB2, CDKN1A, IFI27, TP53
22Afatinib1110.7EGFR, ERBB2
23paraffin4410.7IFI27, CDKN1A, EGFR, KRT13, ERBB2, TP53
24n acetylcysteine4410.7ERBB2, EGFR, TP53, IFI27, CDKN1A
25tamoxifen44 49 28 1113.7TP53, CDKN1A, EGFR, IFI27, ERBB2
26progesterone44 59 28 11 2414.7IFI27, EGFR, NR2F1, CDKN1A, ERBB2, HPGD
27paclitaxel44 49 1112.7TP53, ERBB2, CDKN1A, EGFR, IFI27
28indole-3-carbinol4410.7IFI27, CDKN1A, TP53
29cisplatin44 49 59 1113.7TP53, CDKN1A, EGFR, IFI27, BIRC7, ERBB2
30troglitazone44 28 59 1113.7KRT13, IFI27, FABP4, CDKN1A
31steroid4410.7ERBB2, FGF3, HPGD, FABP4, FABP5, IFI27
32vitamin d4410.7IFI27, CDKN1A, HPGD, KRT13, ERBB2
33mg 13244 5911.6IFI27, EGFR, CDKN1A, TP53
34vegf4410.6EGFR, IFI27, CDKN1A, FGF3, MMP10, ERBB2
35sulindac44 1111.6IFI27, TP53, CDKN1A
36batimastat44 59 1112.6EGFR, MMP10, ERBB2
37ly2940024410.6EGFR, CDKN1A, TP53, ERBB2, IFI27
38topotecan44 1111.6TP53, EGFR, ERBB2
39oligonucleotide4410.6NR2F1, CDKN1A, FGF3, MMP10, TP53, MZF1
40ag 1478 hydrochloride5910.6EGFR, ERBB2
41curcumin4410.6EGFR, CDKN1A, ERBB2, TP53
42ag 4905910.6EGFR, ERBB2
43jnj 28871063 hydrochloride5910.5ERBB2, EGFR
44retinoic acid44 2411.5ELK1, IFI27, FABP5, FABP4, FABP12, EGFR
45iressa5910.5EGFR, ERBB2
46pd1587804410.4EGFR, ERBB2
47pertuzumab44 49 1112.4ERBB2, EGFR
48serine4410.4ELK1, TP53, ERBB2, BIRC7, MMP10, HPGD
49n-(4-hydroxyphenyl)retinamide4410.3TP53, ERBB2, CDKN1A
50roscovitine4410.1TP53, CDKN1A, IFI27

GO Terms for genes affiliated with Bladder Transitional Cell Carcinoma

About this section
Sources:
16Gene Ontology
See all sources

Biological processes related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1phosphatidylinositol-mediated signalingGO:04801510.5EGFR, CDKN1A, FGF3, ERBB2
2neurotrophin TRK receptor signaling pathwayGO:04801110.5ELK1, ERBB2, FGF3, CDKN1A, EGFR
3fibroblast growth factor receptor signaling pathwayGO:00854310.4ERBB2, FGF3, CDKN1A, EGFR
4Fc-epsilon receptor signaling pathwayGO:03809510.4EGFR, CDKN1A, FGF3, ERBB2
5innate immune responseGO:04508710.3ELK1, ERBB2, FGF3, CDKN1A, EGFR
6epidermal growth factor receptor signaling pathwayGO:00717310.3ERBB2, FGF3, CDKN1A, EGFR
7mitotic cell cycle arrestGO:07185010.1CDKN1A, TP53

Molecular functions related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:00471610.4ERBB2, EGFR
2epidermal growth factor-activated receptor activityGO:00500610.1ERBB2, EGFR

Products for genes affiliated with Bladder Transitional Cell Carcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Bladder Transitional Cell Carcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet